Company Overview
Virax Biolabs Group Limited operates as a biotechnology entity focused on the distribution of diagnostics test kits designed for the prevention, detection, diagnosis, and risk management of viral diseases, specifically within the field of T cell in Vitro Diagnostics. The company's portfolio encompasses various in-vitro diagnostics test kits covering respiratory and pregnancy-related applications, positioning it within the broader healthcare sector and the specialized biotechnology industry. As of the latest reporting period, the company maintains a market capitalization of $1.18M, generates annual revenue of $2,986, and employs 19 individuals. These specific valuation and operational figures indicate that the company functions as a small-cap entity with limited revenue generation relative to its market capitalization, suggesting a position in the market where traditional sales revenue does not yet fully reflect the company's current valuation metrics.
Financial Health
The company reported revenue of $2,986 over the trailing twelve-month period, while simultaneously reporting a net income of $-5,643,591 and an EBITDA of $-5,556,497. The substantial negative gap between the minimal revenue figure and the massive negative net income reveals a cost structure characterized by significant operating expenses that far exceed current sales, resulting in a loss of over $5.6 million against less than $3,000 in sales. Free cash flow stands at $-3,539,977, which indicates that the company is consuming cash reserves rather than generating liquidity, thereby limiting its immediate financial flexibility to fund operations or new initiatives without external capital. Analysis of the three primary margins shows a gross margin of 0.0%, an operating margin of -160788.3%, and a profit margin of 0.0%, levels that collectively indicate extreme inefficiency where costs consume nearly all revenue and the operating losses are disproportionately large relative to sales. On the balance sheet, the company holds $3.44M in cash against $537,993 in debt, supported by a current ratio of 11.35, which indicates a highly liquid position regarding short-term obligations despite the net loss. However, the debt-to-equity ratio is 10.60, suggesting a highly leveraged capital structure relative to equity, even though the absolute debt level is low compared to cash holdings. Return on Equity is -83.8% and Return on Assets is -48.4%, metrics that reveal that management effectiveness in generating returns from shareholder capital and total assets is currently negative due to the company's persistent net losses.
Valuation Assessment
The valuation metrics present a complex picture, with a P/E Ratio (TTM) listed as N/A due to the absence of positive earnings, while the Forward P/E is calculated at -0.66. The difference between a non-existent trailing multiple and a negative forward multiple implies that the market is pricing in expectations of future earnings recovery or is valuing the company based on non-earnings multiples such as cash flow or asset value. The price-to-book ratio is 0.20, indicating that the market values the company at 20% of its book value, which suggests the market perceives significant intangible risks or a lack of tangible asset backing relative to the stock price. Alternative valuation metrics include a price-to-sales ratio of 396.03 and an EV/EBITDA of 0.38; the extremely high price-to-sales ratio suggests the stock price is decoupled from current sales performance, while the low EV/EBITDA indicates the enterprise value is minimal relative to the negative earnings base. Regarding price range, the 52-week high is $1.35 and the 52-week low is $0.15, placing the current trading context within a range where the stock has experienced significant volatility over the past year. The beta value is 1.71, which means the stock price is expected to be 71% more volatile than the broader market, reflecting high sensitivity to general market movements and sector-specific news.
Growth & Income
Revenue growth year-over-year is recorded at -67.5%, while earnings growth is N/A due to the company's negative earnings history. The fact that earnings are negative while revenue has contracted by two-thirds implies that the company is simultaneously shrinking its top line and failing to achieve profitability, a trajectory that is not conducive to organic growth or financial stabilization. As a non-dividend payer, the company reports a dividend yield of N/A and a payout ratio of 0.0%, indicating that the company reinvests its limited resources, if any remain after operations, into growth initiatives or retains cash rather than distributing income to shareholders. The overall growth and income profile is characterized by contraction in revenue, a complete absence of current earnings or dividend distributions, and a reliance on existing cash reserves to sustain operations amidst negative operating margins and significant year-over-year revenue declines.